Sign In
Buy VCYT
$48.69
+0.89 (+1.86%)
At Close: Jun 03, 2026
Here's Why Veracyte (VCYT) is a Strong Growth Stock
10:46am, Friday, 15'th Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up
09:26am, Tuesday, 12'th Aug 2025
Veracyte Q2 earnings and revenues beat estimates, fueled by Decipher and Afirma growth, sending shares up over 15%.
Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript
02:20am, Thursday, 07'th Aug 2025
Veracyte, Inc. (NASDAQ:VCYT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Marc A. Stapley - CEO & Director Phillip G.
Veracyte (VCYT) Q2 Revenue Jumps 14%
12:40am, Thursday, 07'th Aug 2025
Veracyte (VCYT) Q2 Revenue Jumps 14%
Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates
07:36pm, Wednesday, 06'th Aug 2025
Veracyte (VCYT) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.3 per share a year ago.
Veracyte Announces Second Quarter 2025 Financial Results
04:05pm, Wednesday, 06'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. “Test
Veracyte (VCYT) Soars 7.0%: Is Further Upside Left in the Stock?
09:06am, Monday, 28'th Jul 2025
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Veracyte Set to Join S&P SmallCap 600
05:58pm, Thursday, 24'th Jul 2025
NEW YORK , July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE: TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. W
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
05:30pm, Thursday, 17'th Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter of 2025
Should You Continue to Hold Veracyte Stock in Your Portfolio Now?
09:41am, Wednesday, 16'th Jul 2025
VCYT's Decipher growth and strong cash position bolster its outlook, but Biopharma headwinds and macro risks loom.
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
04:05pm, Tuesday, 08'th Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance Prostate and Bladder Cancer Resea
Market Growth Driven by Increasing Demand for Real-World Evidence in Drug Development, Rising Focus on Value-Based Healthcare, Growing Cancer Incidence Globally, and Advancements in Data Analytics and
Veracyte to Participate in Upcoming Investor Conferences
05:00pm, Tuesday, 20'th May 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. William Bla
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?
09:40am, Monday, 19'th May 2025
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
